This shows you the differences between two versions of the page.
Both sides previous revision Previous revision Next revision | Previous revision | ||
bacteria:t3e:xopl [2020/07/07 12:01] rkoebnik [XopL] |
bacteria:t3e:xopl [2022/07/13 18:14] (current) rkoebnik [Biological function] |
||
---|---|---|---|
Line 7: | Line 7: | ||
Class: XopL\\ | Class: XopL\\ | ||
Family: XopL\\ | Family: XopL\\ | ||
- | Prototype: | + | Prototype: |
RefSeq ID: [[https:// | RefSeq ID: [[https:// | ||
- | Examples of other sequences: XopL< | + | Examples of other sequences: XopL< |
- | 3D structure: | + | 3D structure: [[https:// |
- | [[https:// | + | |
- | ). Full-length XopL< | + | |
===== Biological function ===== | ===== Biological function ===== | ||
Line 40: | Line 38: | ||
* XopL< | * XopL< | ||
* XopL< | * XopL< | ||
+ | * // | ||
=== Localization === | === Localization === | ||
Line 51: | Line 49: | ||
=== Interaction partners === | === Interaction partners === | ||
- | Unknown. | + | XopL< |
===== Conservation ===== | ===== Conservation ===== | ||
Line 57: | Line 55: | ||
=== In xanthomonads === | === In xanthomonads === | ||
- | Yes in // | + | Yes (//e.g.//, //X. euvesicatoria//, |
=== In other plant pathogens/ | === In other plant pathogens/ | ||
Line 65: | Line 62: | ||
===== References ===== | ===== References ===== | ||
- | Adlung N (2016). Charakterisierung der Avirulenzaktivität von XopQ und Identifizierung möglicher Interaktoren von XopL aus // | + | Adlung N (2016). Charakterisierung der Avirulenzaktivität von XopQ und Identifizierung möglicher Interaktoren von XopL aus // |
+ | |||
+ | Erickson JL, Adlung N, Lampe C, Bonas U, Schattat MH (2018). The // | ||
- | Erickson JL, Adlung N, Lampe C, Bonas U, Schattat MH (2018). The // | + | Jiang W, Jiang BL, Xu RQ, Huang JD, Wei HY, Jiang GF, Cen WJ, Liu J, Ge YY, Li GH, Su LL, Hang XH, Tang DJ, Lu GT, Feng JX, He YQ, Tang JL (2009). Identification of six type III effector genes with the PIP box in // |
- | Jiang W, Jiang BL, Xu RQ, Huang JD, Wei HY, Jiang GF, Cen WJ, Liu J, Ge YY, Li GH, Su LL, Hang XH, Tang DJ, Lu GT, Feng JX, He YQ, Tang JL (2009). Identification of six type III effector | + | Leong JX, Raffeiner M, Spinti D, Langin G, Franz-Wachtel M, Guzman AR, Kim JG, Pandey P, Minina AE, Macek B, Hafrén A, Bozkurt TO, Mudgett MB, Börnke F, Hofius D, Üstün S (2022). A bacterial |
- | Liu Y, Long J, Shen D, Song C (2016). // | + | Liu Y, Long J, Shen D, Song C (2016). // |
- | Popov G, Fraiture M, Brunner F, Sessa G (2016). Multiple // | + | Popov G, Fraiture M, Brunner F, Sessa G (2016). Multiple // |
Singer AU, Schulze S, Skarina T, Xu X, Cui H, Eschen-Lippold L, Egler M, Srikumar T, Raught B, Lee J, Scheel D, Savchenko A, Bonas U (2013). A pathogen type III effector with a novel E3 ubiquitin ligase architecture. PLoS Pathog. 9: e1003121. DOI: [[https:// | Singer AU, Schulze S, Skarina T, Xu X, Cui H, Eschen-Lippold L, Egler M, Srikumar T, Raught B, Lee J, Scheel D, Savchenko A, Bonas U (2013). A pathogen type III effector with a novel E3 ubiquitin ligase architecture. PLoS Pathog. 9: e1003121. DOI: [[https:// | ||
- | Soni M, Mondal KK. (2017). // | + | Soni M, Mondal KK. (2017). // |
- | Yan X, Tao J, Luo HL, Tan LT, Rong W, Li HP, He CZ (2019). A type III effector XopL< | + | Yan X, Tao J, Luo HL, Tan LT, Rong W, Li HP, He CZ (2019). A type III effector XopL< |